Lung cancer combo shows promise after targeted therapy fails
NCT ID NCT05786430
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study tests whether adding chemotherapy to the targeted drug lazertinib can help people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) whose cancer stopped responding to lazertinib alone. About 87 adults will receive the combination and be followed to see how long the cancer stays under control. The goal is to find a new treatment option when the first targeted therapy no longer works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.